AxoGen, Inc. to Present at the Wedbush Healthcare Conference

ALACHUA, Fla., Aug. 3, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, NY.

A live webcast and subsequent archived replay of the Company's presentation may be accessed via the investor relations section of the Company's website.

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance Nerve Graft is processed in the United States by AxoGen. AxoGuard Nerve Connector and AxoGuard Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Michael Polyviou/Doug Sherk - Investor Relations

212.850.6020/415.652.9100

mpolyviou(at)evcgroup(dot)com; dsherk(at)evcgroup(dot)com

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/08/prweb12882332.htm

Michael Polyviou/Doug Sherk - Investor Relations

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!

Already have an account? Log in here.